Digital phenotyping by wearable-driven artificial intelligence in older adults and people with Parkinson’s disease: Protocol of the mixed method, cyclic ActiveAgeing study

Abstract

Background Active ageing is described as the process of optimizing health, empowerment, and security to enhance the quality of life in the rapidly growing population of older adults. Meanwhile, multimorbidity and neurological disorders, such as Parkinson’s disease (PD), lead to global public health and resource limitations. We introduce a novel user-centered paradigm of ageing based on wearable-driven artificial intelligence (AI) that may harness the autonomy and independence that accompany functional limitation or disability, and possibly elevate life expectancy in older adults and people with PD. Methods ActiveAgeing is a 4-year, multicentre, mixed method, cyclic study that combines digital phenotyping via commercial devices (Empatica E4, Fitbit Sense, and Oura Ring) with traditional evaluation (clinical assessment scales, in-depth interviews, and clinical consultations) and includes four types of participants: (1) people with PD and (2) their informal caregiver; (3) healthy older adults from the Helgetun living environment in Norway, and (4) people on the Helgetun waiting list. For the first study, each group will be represented by N = 15 participants to test the data acquisition and to determine the sample size for the second study. To suggest lifestyle changes, modules for human expert-based advice, machine-generated advice, and self-generated advice from accessible data visualization will be designed. Quantitative analysis of physiological data will rely on digital signal processing (DSP) and AI techniques. The clinical assessment scales are the Unified Parkinson’s Disease Rating Scale (UPDRS), Montreal Cognitive Assessment (MoCA), Geriatric Depression Scale (GDS), Geriatric Anxiety Inventory (GAI), Apathy Evaluation Scale (AES), and the REM Sleep Behaviour Disorder Screening Questionnaire (RBDSQ). A qualitative inquiry will be carried out with individual and focus group interviews and analysed using a hermeneutic approach including narrative and thematic analysis techniques. Discussion We hypothesise that digital phenotyping is feasible to explore the ageing process from clinical and lifestyle perspectives including older adults and people with PD. Data is used for clinical decision-making by symptom tracking, predicting symptom evolution, and discovering new outcome measures for clinical trials.

Exploring active ageing in a community-based living environment: an ethnographic study in the Western Norway context

“…The study is part of an umbrella project called ActiveAgeing, which aims to investigate the current possibilities for enhanced activity and quality of life in healthy older adults and people with Parkinson’s disease. A method paper for the ActiveAgeing project was published in 2022 ( 11 ).…”

The Difficulties of Managing Pain in People Living with Frailty: The Potential for Digital Phenotyping

“…Digital phenotyping is concerned with observable characteristics in digital form, more specifically those that are obtained from sensing-capable devices and other sensors, and may present deeper and novel information, adding to existing clinical approaches [ 20 , 21 ]. Digital phenotyping is defined as the use of moment-to-moment quantitative and descriptive data that are automatically generated (for example, heart rate, blood pressure, skin conductance, and movement) and collected by technological devices such as wearables, mobile devices, or video cameras [ 22 , 23 ]. The outcomes of digital phenotyping we designate as “digital biomarkers”, which are meant to complement traditional biomarkers (for example, non-specific autonomic, behavioural, and reflex responses) and can shed light on individualised descriptions of the complex, nonlinear, and heterogenous processes specific to the human body.…”

Artificial Intelligence‐Based Medical Sensors for Healthcare System

“…Skin-based wearable devices have the considerable advantages of being able to simultaneously monitor multiple physiological indicators and biomarkers in disease monitoring. [82][83][84][85][86] Diabetes is one of the most common chronic diseases, which need to check the blood glucose level of patients daily for continuous management. Lee et al integrated monitoring and treatment into one wearable device based on functionalized chemical vapor deposition (CVD) graphene.…”